-
Product Insights
NewSmoothened Homolog – Drugs In Development, 2024
The Smoothened Homolog pipeline drugs market research report outlays comprehensive information on the Smoothened Homolog targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Respiratory, Musculoskeletal Disorders, and Immunology which include indications of Medulloblastoma, Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), Idiopathic Pulmonary Fibrosis, Fibrosis, Bone Disorders, and Graft Versus Host Disease (GVHD)....
-
Product Insights
NewDisks Large Homolog 4 – Drugs In Development, 2024
The Disks Large Homolog 4 pipeline drugs market research report outlays comprehensive information on the Disks Large Homolog 4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Cardiovascular, Central Nervous System, and Ophthalmology which include indications of Acute Ischemic Stroke, Subarachnoid Hemorrhage, Unspecified Central Nervous System Disorders, Traumatic Brain Injury, and Ophthalmology. It also reviews key players...
-
Product Insights
NewSon Of Sevenless Homolog 1 – Drugs In Development, 2024
The Son Of Sevenless Homolog 1 pipeline drugs market research report outlays comprehensive information on the Son Of Sevenless Homolog 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Respiratory, and Immunology which include indications of Solid Tumor, Non-Small Cell Lung Cancer, Pulmonary Fibrosis, and Systemic Sclerosis (Scleroderma). It also reviews key players involved in Son...
-
Product Insights
NewEgl Nine Homolog 1 – Drugs In Development, 2024
The Egl Nine Homolog 1 pipeline drugs market research report outlays comprehensive information on the Egl Nine Homolog 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Hematological Disorders, Dermatology, Infectious Disease, and Oncology which include indications of Anemia in Chronic Kidney Disease (Renal Anemia), Wounds, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress...
-
Product Insights
NewNeurogenic Locus Notch Homolog Protein 1 – Drugs In Development, 2024
The Neurogenic Locus Notch Homolog Protein 1 pipeline drugs market research report outlays comprehensive information on the Neurogenic Locus Notch Homolog Protein 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Metabolic Disorders, Hematological Disorders, and Central Nervous System which include indications of Oncology, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Type 1 Diabetes (Juvenile Diabetes),...
-
Product Insights
NewDnaJ Homolog Subfamily C Member 15 – Drugs In Development, 2024
The DnaJ Homolog Subfamily C Member 15 pipeline drugs market research report outlays comprehensive information on the DnaJ Homolog Subfamily C Member 15 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Gastrointestinal, Oncology, Genito Urinary System, and Genetic Disorders which include indications of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Hepatic Injury, Breast Cancer, Acute Renal Failure (ARF) (Acute Kidney...
-
Innovation Ranking
Innovation Ranking – Homology Medicines Inc
Homology Medicines Inc (Homology) is a genetic medicines company that discovers and develops gene therapies to treat genetic disorders. The company is investigating pipeline programs HMI-102, a gene therapy for the treatment of phenylketonuria (PKU); and HMI-202, an investigational gene therapy targeting metachromatic leukodystrophy. It is also evaluating HMI-103, an investigational gene editing program for the treatment of pediatric phenylketonuria, and HMI-203, an investigational gene therapy for the treatment of Hunter syndrome. Homology gene-editing technology is used in DNA repairs,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olaparib in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olaparib in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olaparib in Head And Neck Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Head And Neck Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olaparib in Head And Neck Cancer Drug Details: Olaparib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olaparib in Osteosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Osteosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olaparib in Osteosarcoma Drug Details: Olaparib (Lynparza) is an antineoplastic agent. It...